What is it about?
Microorganisms, including fungi, have the ability to develop resistance to the drugs commonly used to treat the infections they cause. The monitoring of drug resistance patterns is present is most regions around the globe, but there is a lack of data from sub-Saharan Africa. In this review we looked at published studies on Candida drug resistance in the subcontinent.
Featured Image
Why is it important?
We found that the drug resistance patterns are not uniform in the different regions where studies have been conducted. Due to the emergence of Candida drug resistance to widely used antifungal drugs, we proposed a revision of current prescribing guidelines and the establishment of surveillance programmes in sub-Saharan Africa.
Perspectives
Mortality rates due to antimicrobial resistant infections is on the increase. So is the rate of nosocomial / opportunistic infection. An awareness of changes in antimicrobial profiles of opportunistic pathogens is imperative if these are to be controlled.
Emerita Professor Charlene WJ Africa
University of the Western Cape
Read the Original
This page is a summary of: Candida antifungal drug resistance in sub-Saharan African populations: A systematic review, F1000Research, December 2016, Faculty of 1000, Ltd.,
DOI: 10.12688/f1000research.10327.1.
You can read the full text:
Contributors
The following have contributed to this page
